CytoArm’s Bi-functional Antibody (BsAb) | Revolutionizing Cancer Immunotherapy

Introduction to CytoArm’s “Armour”: Bi-functional Antibody (BsAb)

CytoArm has engineered a series of unique bi-functional antibodies (BsAb) that act as a guidance system for T cells in targeting and destroying cancer cells. The BsAb’s dual-arm structure enables it to engage two distinct targets: one arm binds to a T-cell receptor (typically CD3) on cytotoxic T cells, activating them, while the other arm binds to a specific antigen on the surface of cancer cells. This precise targeting mechanism directs T cells to infiltrate the cancer cells, inducing direct cell-mediated cytotoxicity and the destruction of the tumor.

Key Functions of CytoArm’s BsAb

CytoArm’s Bi-functional Antibody (BsAb) works by utilizing one arm to bind to CD3 receptors on T cells, activating their cytotoxic potential. Simultaneously, the other arm targets tumor-specific antigens on cancer cells, directing the activated T cells to attack. Once engaged, the T cells release cytotoxic granules, inducing apoptosis, or programmed cell death, in the cancer cells.

Armouring

One arm of the BsAb binds to CD3 receptors on T cells, activating their cytotoxic potential.

Targeting

The other arm binds to tumor-specific antigens on cancer cells.

Activation

This binding activates the T cells and directs them to attack the cancer cells

Destruction

T cells release cytotoxic granules that induce apoptosis (programmed cell death) in the cancer cells

CytoArm’s BsAb:
Limitless Potential for Drug Development

CytoArm holds comprehensive patents for its bi-specific antibody “armour” platform.

By modifying the tumor-targeting components of our BsAb, we can develop nearly limitless antibody therapies.

Our BsAb platform targets a wide range of common and novel cancer markers.

Collaborative Opportunities with CytoArm’s BsAb:

Co-development of Specific Armed-T Cells:
Partner with CytoArm to create custom BsAb therapies for specific cancers.

Optimize Existing T-cell Therapies:
Enhance your current cell therapy platforms with the precision and efficacy of CytoArm’s BsAb technology.

Teamwork Hands And Collaboration With A Team Of B 2023 11 27 05 19 43 Utc